PD-L1 Inhibitors Development Services
Alfa Cytology moved into drug development for leukemia and seeks to assist researchers in their quest for effective PD-L1 inhibitors for leukemia through the provision of comprehensive services. By combining the expertise of our technical team and the use of cutting-edge platforms, we are concentrated on the design of drugs that target PD-L1 and on providing a novel immunotherapy strategy with PD-1 and PD-L1 blockade in leukemia therapy.
Introduction to PD-L1 Inhibitors and Leukemia
PD-L1 on the surface of cells interacted with PD-1 on the surface of lymphocytes to result in the inhibition of lymphocyte function and apoptosis induction in the activated lymphocytes. PD-L1 overexpression in chronic lymphocytic leukemia and acute myeloid leukemia has been noted. The PD-L1 checkpoint inhibitors have been approved for the treatment of lymphomas and various solid tumors. However, PD-L1 drugs targeting leukemia are still in the developmental phase.
Fig. 1. Mechanism of action of PD-1 and PD-L1 inhibitors. (Gong, J. et al., 2018)
Alfa Cytology has focused on PD-L1 as a target immune checkpoint in the evasion of an immune response in cancer for leukemia therapy. The targets of PD-L1 that we have supported include monoclonal antibodies and small-molecule inhibitors. Here are the services we provide in detail.
PD-L1 Agents Development Services
PD-L1 Inhibitors
Alfa Cytology specializes in development for the next-generation PD-L1 inhibitors against challenges ranging from poor permeability to long half-action.
- Small molecules
- Peptides
- Macrocyclic compounds
PD-L1 mAb
Alfa Cytology provides development services for monoclonal antibodies (mAbs) that block the PD-L1, utilizing the therapeutic antibody discovery platform to develop PD-L1 mAbs.
- Molecular modeling
- Protein design
PD-L1 ADCs
Alfa Cytology offers provides service for the development of antibodies-drug couplers (ADCs), linked with anti-PD-L1 mAb in achieving bifunctional PD-L1-directed ADCs.
Preclinical Testing for PD-L1 Inhibitor Development
Development Product characterization, in functional properties, is the basis of PD-L1 inhibitors development. A bouquet of validated assays is being offered for their in vitro characterization. Our other services also embrace comparison between clones or assessment against approved reference products.
PD-L1 Blockade Assay
PD-L1 Blockade Assay features two genetically engineered cell lines co-cultured: effector cells expressing PD-1 and antigen-presenting cells expressing PD-L1. These two cell lines co-cultured allow the engagement of PD-L1 with PD-1, subsequently inhibiting TCR signal transduction in the effector cells.
Antibody-dependent Cell-mediated Cytotoxicity (ADCC) Assays
Our ADCC detection services evaluate PD-L1 mAbs for leukemia drug development. Measurement of cytotoxicity can be achieved using either non-radioactive release assays or flow cytometry with fluorescent dyes to distinguish between target cells and effector cells or viable cells and dead cells.
Antigen-specific T Cell Recall and Activation Assay
Inhibition of the PD-1 pathway has been shown to encourage memory T cells which enhance anti-tumor efficacy. This effect was studied using an in vitro antigen recall and activation assay to assess the generation of memory T cells.
After in vitro characterization, the advancement of the most promising candidate drugs can include in vivo models. We provide validated leukemia models, including but not limited to humanized models, xenograft models, and transgenic models. We can help you pick the right model for PD-L1 inhibitor development.
After in vitro characterization, the development of the most promising candidate drugs can be advanced through in vivo models. We offer validated leukemia models, including but not limited to humanized models, xenograft models, and transgenic models. We will assist you in selecting the most suitable model for the development of PD-L1 inhibitors.
We utilize a risk-based approach that is both efficient and organized in terms of the high quality required for your pharmaceutical products. Our highly experienced toxicology consultants assist in project execution with either outsourcing or support for your team.
Advantages of Our Services
Customized
Solutions
Regulatory
Compliance
Timely
Delivery
Highly
Confidential
Alfa Cytology has several years of experience in drug discovery, with expertise in development and testing of PD-L1 checkpoint inhibitors in leukemia. Our services in PD-L1 inhibitors development focus on the whole range of drug discovery, target identification, and validation to lead optimization and preclinical testing to realize an efficient development pathway. Please contact us to learn how we can assist you in the development of anti-PD-1L drugs and leukemia models.
Reference
- Gong, J.; et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. Journal for Immunotherapy of Cancer. 2018, 6: 1-18.